Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

[1]  H. Sandler,et al.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[3]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ananya Choudhury,et al.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. , 2010, Cancer research.

[5]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[6]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[7]  N. Vogelzang,et al.  The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. , 1992, The Journal of urology.

[8]  I. Tannock,et al.  Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[10]  Nicholas D James,et al.  Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. , 2014, European urology.

[11]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[12]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[13]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[14]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .

[15]  R. Huddart,et al.  Results of the SPARE Feasibility Study – Selective Bladder Preservation Against Radical Excision in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder (CRUK/07/011) , 2012 .

[16]  A. Zietman,et al.  Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. , 2001, Urology.

[17]  J. Donovan,et al.  Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011) , 2011, Trials.

[18]  J. Cheville,et al.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer , 2015, Modern Pathology.

[19]  David C. Smith,et al.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). , 2009, The Journal of urology.

[20]  R. Cowan,et al.  Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Williams,et al.  Basic clinical radiobiology , 1994, British Journal of Cancer.

[22]  A. Zietman,et al.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. , 2013, The Lancet. Oncology.

[23]  E. Wallen,et al.  Robotic-assisted laparoscopic intracorporeal urinary diversion , 2010 .

[24]  R. Hautmann,et al.  The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. , 1999, The Journal of urology.

[25]  C. Sternberg,et al.  Can patient selection for bladder preservation be based on response to chemotherapy? , 2003, Cancer.

[26]  P. Hoskin,et al.  Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[28]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Zietman,et al.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. , 2003, The Journal of urology.

[30]  T. Kessler,et al.  Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. , 2005, The Urologic clinics of North America.

[31]  K. Guru,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[32]  D. Dearnaley,et al.  Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy). , 2014 .